It's How Medicine Should Be®


French German Italian Portuguese Russian

Treatment Study for Non-Small Cell Lung Cancer and Adenocarcinoma

Clinical Trial Title: 
A phase 1b open-label study of PEGylated recombinant human hyaluronidase (PEGPH20) combined with pembrolizumab in subjects with selected hyaluronan-high solid tumors.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mary Jo Fidler, MD
Clinical Trial Protocol Description: 

The purpose of the study is to test the investigational drug PEGPH20 in combination with the immunotherapy antibody, pembrolizumab in subjects with non-small cell lung cancer (NSCLC) and a type of gastric cancer called adenocarcinoma.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have NSCLC or gastric adenocarcinoma.
  • Have HA-high levels from tumor biopsies.
  • Have tissue available for HA-selection and PD-L1 testing.

You will be excluded from the study if any of the following criteria apply to you:

  • Have had previous treatment with pembrolizumab, nivolumab or other programmed cell death-1 antibody (anti-PD-1) or PD-1 ligand-antibody (anti-PD-L1) agents.
  • Have cardiac disease or myocardial infarction, cerebrovascular accident or transient ischemic attack.
  • Have brain metastases.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Gastrointestinal Cancers
Lung and Chest Tumors
Contact Phone: 
(312) 563-3921
Contact Name: 
Emily Rubenstein, RN